1. Morvan's syndrome with hypercoagulable condition in a patient positive for anti-CASPR2 antibodies: A case report.
- Author
-
Pang X, Li Y, Liu Z, Mao Y, Li X, Gao L, Geng Y, and Meng L
- Subjects
- Humans, Male, Adult, Plasmapheresis, Thrombophilia immunology, Thrombophilia drug therapy, Autoantibodies blood, Autoantibodies immunology, Membrane Proteins immunology, Nerve Tissue Proteins immunology
- Abstract
Rationale: The phenomenon of hypercoagulability has not been previously documented in individuals with Morvan's syndrome, especially in those associated with contactin-associated protein-like receptor 2 (CASPR2)., Patient Concerns: A previously healthy 32-year-old Chinese male was admitted to the hospital with central and peripheral neurologic symptoms. The patient was tested positive for anti-CASPR2 antibodies, and also presented with an activated coagulation state on admission, characterized by a low activated partial thromboplastin time and a high platelet count. With gradual improvement of clinical symptoms, activated partial thromboplastin time, and platelet count returned to normal. Simultaneously, anti-CASPR2 antibody titers significantly decreased and eventually became undetectable., Diagnoses: The patient was diagnosed as Morvan's syndrome with positive anti-CASPAR2 antibodies accompanied with hypercoagulable state., Interventions: Plasmapheresis was administered to improve the symptoms combined with prednisolone acetate therapy., Outcomes: The patient experienced complete resolution of all symptoms during hospitalization and generally recovery after 2 months of discharge., Lessons: Emphasis should be directed towards hypercoagulability in individuals diagnosed with Morvan's syndrome, particularly those presenting with positive anti-CASPR2 antibodies. Anticoagulant therapy may represent a novel therapeutic approach for individuals afflicted with Morvan's syndrome and exhibiting positivity for anti-CASPR2 antibodies., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF